The $132.3M raise provides a multi-year cash runway through key Phase 3 readouts. Monitor Q3 2026 for CHAPTER-3 topline data, which is the primary catalyst. The offering was fully subscribed with underwriter option exercise, indicating strong institutional demand despite dilution.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $31.25entry
- T+1 · 6mo ago 0.00%α −0.54% · $31.25
- T+5 · 6mo ago −7.81%α −7.89% · $28.81
- T+20 · 5mo ago +0.83%α +2.56% · $31.51
- T+60 · 3mo ago +10.24%α +5.86% · $34.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' option. The proceeds provide a significant cash runway for late-stage clinical programs, including the pivotal Phase 3 CHAPTER-3 study for HAE prevention with topline data expected in Q3 2026.
Key Financial Metrics
Key Facts
- Closed underwritten offering of 4,455,863 ordinary shares at gross proceeds of ~$132.3M
- Underwriters exercised option in full for an additional 581,199 shares
- Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acted as joint book-running managers
- Proceeds will fund late-stage clinical programs including CHAPTER-3 Phase 3 study for HAE prevention
- Topline data from CHAPTER-3 study anticipated in Q3 2026
- CREAATE Phase 3 study for AAE-C1INH is ongoing
Financial Impact
$132.3M gross proceeds from offering
Risk Factors
- Dilution of ~4.5M shares (approximately 10-15% of pre-offering shares outstanding)
- Clinical trial risk for CHAPTER-3 and CREAATE studies
- No revenue-generating products approved yet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292354 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers